Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The patient passed away after an acute systemic infection.
Needham analyst Gil Blum downgraded Rocket Pharmaceuticals from Buy to Hold, with a Nil price forecast from $42 earlier. The analyst cited increased uncertainty around the company's main value driver as the key reason for the downgrade.'We continue to have a favorable view of RP-A501's efficacy; however, we see increased uncertainty for the product given safety concerns,' Blum said in an analyst note.
Blum anticipates limited readthrough to Rocket's other AAV programs, which utilize simpler immunosuppression regimens.
Chardan Research analyst Geulah Livshits also lowered its price target from $46 to $17 while maintaining the Buy rating.
While the disclosure does not negate the benefit reported for the program, the patient death and commentary regarding instances of TMA impact the benefit/risk profile of RP-A501, Livshits said in an analyst note.
Livshits reduced the probability of success from 70% to 40%, given CBER leadership's focus on benefit/risk, pending more details regarding agency feedback and next steps.
The analyst projects a slower uptake among the Danon population (3.6% by 2030E), assuming greater caution among prescribers.
Chardan notes the company hasn't revealed how many patients have been treated in the trial so far but said the study is currently over-enrolled, with more patients ready to begin treatment.
Management mentioned several possible next steps, such as switching to a simpler immunomodulatory treatment, using existing complement inhibitors known to be safe, and continuing to exclude patients who are genetically predisposed to complement activation.
Chardan highlights that it's still unclear whether other immunomodulatory treatments could reduce the risk of TMA. There's no timeline for when the company might align with the FDA and restart the trial. Additional changes like enrolling more patients may be required, which could cause further delays.
Given this uncertainty, the topline results are expected to come later than the previously guided mid-2026 timeframe.
Other analyst reactions:
Jefferies downgraded Rocket Pharmaceuticals from Buy to Hold and lowered the price target from $29 to $2.5.
Leerink Partners downgraded Rocket Pharmaceuticals from Outperform to Market Perform, lowering the price target from $37 to $8.
Scotiabank maintains Rocket Pharmaceuticals with a Sector Outperform, lowering the price target from $51 to $19.
Price Action: RCKT stock is trading higher by 6.44% to $2.48 at last check Wednesday.
Read Next:Image via Shutterstock
Date
Firm
Action
From
To
Feb 2022
SVB Leerink
Maintains
Outperform
Dec 2021
Chardan Capital
Maintains
Buy
Aug 2021
SVB Leerink
Maintains
Outperform
View More Analyst Ratings for RCKT
View the Latest Analyst Ratings
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Rigetti Computing Stays The Course In Push For Quantum Advantage
Rigetti Computing, Inc. (NASDAQ:RGTI) shares are trading higher on Wednesday. The firm released its second-quarter results after Tuesday's closing bell, with quarterly losses of 13 cents per share, which missed the analyst consensus estimate for losses of 6 cents. Quarterly revenue came in at $1.8 million, which missed the analyst consensus estimate of $1.88 million and is down from revenue of $3.086 million from the same period last the miss, Wall Street analysts maintained bullish outlooks, pointing to progress on Rigetti's technology roadmap. Needham: Scaling Progress Strengthens Confidence Analyst N. Quinn Bolton reiterated the Buy rating on the stock, with a price forecast of $18. Bolton said Rigetti met its mid-year goal with a four-chiplet, 36-qubit Cepheus-1-36Q QPU reaching 99.5% median two-qubit fidelity. He added that this strengthens management's confidence in delivering a >100-qubit system with 99.5% median two-gate fidelity by year-end. He also noted quantum advantage remains about four years away and will require meeting four key specifications. Rigetti, which went public in February 2022 as the second pure-play quantum firm, is a full-stack pioneer with proprietary quantum-classical infrastructure and is well-positioned to benefit as the industry advances in the near and long term. Bolton added that its approach, built on scalable multi-chip processors designed, manufactured and housed at Fab-1, lets commercial and government customers explore applications while the company and peers work toward fully fault-tolerant systems. According to the analyst, existing partnerships and customer ties should lead to follow-on R&D agreements and larger opportunities as scaling continues. Analysts expect that from 2026 onward, the company will raise its qubit count to the hundreds and improve median two-qubit gate fidelity to 99.9%. They also anticipate the introduction of qLDPC-based quantum error correction. Benchmark: Roadmap to 1,000 Qubits Analyst David Williams reiterated the Buy rating, raising the price forecast to $20 from $14. Williams said Rigetti remains on track to deliver a 100-qubit, multi-chiplet QPU with 99.5% two-qubit gate fidelity by year-end, a key step toward quantum advantage. He noted the newly released Cepheus-1 met that fidelity goal while cutting error rates, debuting what he views as the industry's largest multi-chip processor for quantum computing and reinforcing the scalability of Rigetti's architecture. He added that these gains firm up the roadmap to a 1,000+-qubit system with 99.9% fidelity, built-in error correction, and sub-50 ns gate times needed for advantage. While management still sees a three-to-four-year timeline to reach that threshold, the analyst expects meaningful revenue opportunities well before then. Williams also highlighted that Rigetti increased cash by $350 million to about $570 million during the period, which he believes is sufficient to fund continued investment through commercialization. Management said the long-term objective over the next three to four years is a 1,000-qubit system targeting 99.9% fidelity, built-in error correction, and sub-50 ns gates, enabled by advances in cabling, cryogenics, and chiplet density. They also argued the chiplet architecture is the only practical route to scale and noted strong patent protection. Price Action: RGTI shares are trading higher by 1.31% to $16.41 at last check Wednesday. Read Next:Image via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Rigetti Computing Stays The Course In Push For Quantum Advantage originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
11 hours ago
- Yahoo
Veteran analyst who predicted Rocket Lab's surge makes surprising move
Veteran analyst who predicted Rocket Lab's surge makes surprising move originally appeared on TheStreet. Having surged more than 70% this year, Rocket Lab () has emerged as one of the hottest names in the space sector. The company, founded in 2006 in New Zealand, is now headquartered in California, specializing in satellite launches and space systems. It has become a key player in the commercial space race to compete with Elon Musk's SpaceX. Rocket Lab's stock soared 360.58% in 2024, fueled by record launch cadence, growing defense contracts, and investor enthusiasm for Neutron, the company's larger, next-gen reusable Aug. 7, Rocket Lab posted second-quarter revenue of $144.5 million, topping analyst estimates of $135.41 million. This was driven by 'strong operational performance and program execution,' according to the company's founder and CEO Peter Beck. Yet the company is not currently profitable. It reported a loss of 13 cents per share, wider than the 8-cent loss expected. For the third quarter, Rocket Lab expects revenue of $145 million to $155 million, close to the $150.45 million consensus. Adjusted gross margins are projected between 39% and 41%. Beck said the third quarter could be "another potential record quarter." He also said the company is "on track for a record year of launches and spacecraft delivery." Some analysts kept a bullish outlook following the earnings beat, even if the stock is trading at a very high price-to-sales ratio (P/S) of 43, which is typically unsustainable. Wall Street raises Rocket Lab stock price target after earnings Several analysts have raised their stock price target for Rocket Lab. Needham raised its price target on Rocket Lab to $55 from $45 and reiterated a buy rating, according to thefly's reporting. The firm pointed to the company's strong second-quarter results, with revenue, EBITDA, and guidance all coming in above consensus. Management also sounded more confident about sustaining revenue growth and expanding gross margins, Needham analyst Mike Leschock lifted his price target on Rocket Lab to $50 from $40 and maintained an overweight rating, citing stronger margins than his model anticipated and growing confidence in the progress of the Neutron rocket. KeyBanc noted that while Rocket Lab's timeline to breakeven free cash flow is pushed out 3-6 months, but said this is due to increased investment in high-growth avenues, and Rocket's cash position gives KeyBanc confidence in its ability to execute on these initiatives. The stock closed at $43.43 on Aug. 12, up 70% over the past two months, but not everyone on Wall Street is convinced it can keep climbing. One veteran analyst sounds the alarm on Rocket Lab Stephen Guilfoyle, a 30-year Wall Street veteran who now runs Sarge986 LLC, a family trading operation, has warned about Rocket Lab as 'profitability' concerns emerge, he wrote on TheStreet Pro. Guilfoyle, who has successfully traded Rocket Lab stocks with a 382% gain, said he was not entirely satisfied with the company's financials. "The balance sheet is strong, cash flows are not. Gross margins are improving. Net profitability appears to be moving further away," he wrote, adding that the guidance was fine but did not leave him amazed. More Wall Street Analysts: B of A drops shocking price target on hot weight-loss stock post-earnings Analyst reboots SoFi Technologies price target after capital raise Analysts tweak Super Micro stock price target after earnings For the first half of 2025, Rocket Lab posted operating cash flow of -$77.467 million and capex of $60.719 million, resulting in free cash flow of -$138.186 million. That's a sharper cash burn than the -$50.109 million recorded in the same period last year. "Beck mentioned the term long-term profitability once in the press release. Neither the word 'profit' nor 'profitability' came up at all during the call. I thought that mildly troubling," Guilfoyle said. Guilfoyle canceled the stock's $51 target on July 17 when shares were going 'parabolic.' He now warns the stock has returned to what he calls an 'old pitchfork' model and appears to be 'fumbling around for support at its 21-day EMA.' He cautioned that if the stock loses that technical support, swing traders could likely start selling the stock. "I do think the time has come to de-emphasize RKLB," Guilfoyle said. He plans to cut his stake in Rocket Lab but without fully exiting. The stock is currently Guilfoyle's third-largest holding, and he plans to trim it down to around his fifth or sixth-largest analyst who predicted Rocket Lab's surge makes surprising move first appeared on TheStreet on Aug 13, 2025 This story was originally reported by TheStreet on Aug 13, 2025, where it first appeared. Sign in to access your portfolio
Business Wire
a day ago
- Business Wire
CuriosityStream Announces Pricing of Secondary Public Offering of Common Stock
SILVER SPRING, Md.--(BUSINESS WIRE)--CuriosityStream, Inc. (the 'Company') (Nasdaq: CURI), a leading global factual media company, has announced today the pricing of an underwritten secondary offering by a selling stockholder of 7,000,000 shares of the Company's common stock, par value $0.0001 per share (the 'Common Stock'), at a price to the public of $3.50 per share. The offering is expected to close on August 14, 2025, subject to the satisfaction of customary closing conditions. The offering includes an option for the underwriters to purchase 1,050,000 additional shares within 30 days at the public offering price, less underwriting discounts and commissions. Needham & Company and Craig-Hallum are serving as joint book-running managers for the offering. Roth Capital Partners is serving as co-manager for the offering. The selling stockholder will receive all the net proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering. The offering is being conducted through a shelf registration statement on Form S-3 that was declared effective on May 3, 2022. Before you invest, you should read the prospectus supplement and accompanying prospectus forming a part of that registration statement and other documents the Company has filed with the Securities and Exchange Commission ('SEC') for more complete information about the Company and the offering. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering that has been filed with the SEC, as well as copies of the final prospectus supplement, once available, may be obtained for free on the SEC's website at or from Needham & Company, LLC, 250 Park Avenue, 10th Floor, New York, NY 10177, Attn: Prospectus Department, prospectus@ or by telephone at (800) 903-3268 or from Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 323 North Washington Ave., Minneapolis, MN 55401, by telephone at (612) 334-6300 or by email at prospectus@ This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Cautionary Statements Regarding Forward-Looking Information Certain statements in this press release may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, including statements regarding the size, terms, conditions, timing and use of proceeds of the offering. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words 'believes,' 'estimates,' 'expects,' 'projects,' 'forecasts,' 'may,' 'will,' 'should,' 'seeks,' 'plans,' 'scheduled,' 'anticipates,' 'predicts' or 'intends' or similar expressions. Such forward-looking statements involve risks and uncertainties that may cause actual events, results or performance to differ materially from those indicated by such statements. Certain of these risks are identified and discussed under 'Risk Factors' in CuriosityStream's Annual Report on Form 10-K for the year ended December 31, 2024, that we filed with the Securities and Exchange Commission (the 'SEC') on March 25, 2025, and in CuriosityStream's other SEC filings. These risk factors are important to consider in determining future results and should be reviewed in their entirety. Forward-looking statements are based on the current belief of the management of CuriosityStream, based on currently available information, as to the outcome and timing of future events, and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. However, there can be no assurance that the events, results or trends identified in these forward-looking statements will occur or be achieved. Forward-looking statements speak only as of the date they are made, and CuriosityStream is not under any obligation, and expressly disclaims any obligation to update, alter or otherwise revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Readers should carefully review the statements set forth in the reports that CuriosityStream has filed or will file from time to time with the SEC. In addition to factors previously disclosed in CuriosityStream's reports filed with the SEC and those identified elsewhere in this communication, the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: (i) risks related to CuriosityStream's ability to maintain and develop new and existing revenue-generating relationships and partnerships or to significantly increase CuriosityStream's subscriber base and retain customers; (ii) the effects of pending and future legislation; (iii) risks of the internet, online commerce and media industry; (iv) the highly competitive nature of the internet, online commerce and media industry and CuriosityStream's ability to compete therein; (v) litigation, complaints, and/or adverse publicity; (vi) privacy and data protection laws, privacy or data breaches, or the loss of data; and (vii) the ability to license content for purposes of training generative artificial intelligence models. Readers should carefully review the statements set forth in the reports that CuriosityStream has filed or will file from time to time with the SEC. About CuriosityStream Inc. CuriosityStream Inc. is the entertainment brand for people who want to know more. The global media company is home to award-winning original and curated factual films, shows, and series covering science, nature, history, technology, society, and lifestyle. With millions of subscribers worldwide and thousands of titles, the company operates the flagship Curiosity Stream SVOD service, available in more than 175 countries worldwide; Curiosity Channel, the linear television channel available via global distribution partners; Curiosity University, featuring talks from the best professors at the world's most renowned universities as well as courses, short and long-form videos, and podcasts; Curiosity Now, Curiosity Explora, and other free, ad-supported channels; Curiosity Audio Network, with original content and podcasts; and Curiosity Studios, which oversees original programming. Curiosity Inc. is a wholly owned subsidiary of CuriosityStream Inc. (Nasdaq: CURI).
